Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
F Ravandi, C Arana Yi, J E Cortes, M Levis, S Faderl, G Garcia-Manero, E Jabbour, M Konopleva, S O'Brien, Z Estrov, G Borthakur, D Thomas, S Pierce, M Brandt, K Pratz, R Luthra, M Andreeff, H Kantarjian
